Galecto, Inc.
Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.
GLTO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US36322Q1076
- LEI:
- Country:
- United States of America
- Address:
- 75 STATE STREET, 2109 BOSTON
- Website:
- https://galecto.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Galecto, Inc. is a clinical-stage biotechnology company that pioneers novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its extensive research in galectin biology to develop galectin-3 modulators, targeting key pathways in fibrosis and cancer progression. Galecto has expanded its oncology pipeline to include dual ENL-YEATS and FLT3 inhibitors for treating specific genetic subsets of acute myeloid leukemia (AML). Its research focuses on critical disease drivers in various cancers, including melanoma and carcinomas, as well as severe fibrotic liver conditions. The company's mission is to develop highly efficacious and well-tolerated treatments to extend and improve the quality of life for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Galecto, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Galecto, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Galecto, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
